Docetaxel in combination with epirubicin in metastatic breast cancer: Pharmacokinetic interactions

Farmaco

Volumn 54, Issue 11-12, 1999, Pages 733-739

  Ceruti, Maurizio ^a   Tagini, Valentina ^a   Recalenda, Valeria ^a   Arpicco, Silvia ^a   Cattel, Luigi ^a   Airoldi, Mario ^b   Bumma, Cesare ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Breast cancer; Docetaxel; Epirubicin; Pharmacokinetics

Indexed keywords

DOCETAXEL; EPIRUBICIN; POLYSORBATE 80;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG STRUCTURE; FEMALE; HUMAN; METASTASIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; EPIRUBICIN; FEMALE; HUMANS; PACLITAXEL; SPECTROPHOTOMETRY, ULTRAVIOLET; TAXOIDS;

EID: 0033405876     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(99)00092-0     Document Type: Article

References (40)

1. Fulton B., Spencer C.M. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs. 51:1996;1075-1092.
2. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann. Rev. Med. 48:1997;353-374.
3. Horwitz S.B. Mechanism of action of taxol. Trends Pharmacol. Sci. 13:1992;134-136.
4. Guéritte-Voegelein F., Guénard D., Lavelle F., Le Goff M.-T., Mangatal L., Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem. 34:1991;992-998.
5. Bissery M.C., Guénard D., Guéritte-Voegelein F., Lavelle F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 51:1991;4845-4852.
6. Ringel I., Horwitz S.B. Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J. Natl. Cancer Inst. 83:1991;288-291.
7. Hanauske A.R., Degen D., Hilsenbeck S.G., Bissery M.C., Von Hoff D.D. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs. 3:1992;121-124.
8. Trudeau M.E., Eisenhauer E.A., Higgins B.P., Letendre F., Lofters W.S., Norris B.D., Vandenberg T.A., Delorme F., Muldal A.M. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J. Clin. Oncol. 14:1996;422-428.
9. Hudis C.A., Seidman A.D., Crown J.P., Balmaceda C., Freilich R., Gilewski T.A., Hakes T.B., Currie V., Lebwohl D.E., Baselga J., Raptis G., Gollub M., Robles M., Bruno R., Norton L. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14:1996;58-65.
10. Chevallier B., Fumoleau P., Kerbrat P., Dieras V., Roche H., Krakowski I., Azli N., Bayssas M., Lentz M.A., Van Glabbeke M. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperarative Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 13:1995;314-322.
11. Fumoleau P., Chevallier B., Kerbrat P., Dieras V., Azli N., Bayssas M., Van Glabbeke M. Current status of Taxotere (docetaxel) as a new treatment in breast cancer. Breast Cancer Res. Treat. 33:1995;39-46.
12. Cerny T., Kaplan S., Pavlidis N., Schoffski P., Epelbaum R., van Meeerbeek J., Wanders J., Franklin H.R., Kaye S. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br. J. Cancer. 70:1994;384-387.
13. Rigas J.R. Docetaxel in stage III and IV non-small cell lung cancer. Eur. J. Cancer (suppl. 4). 31A:1995;S18-S20.
14. Fossella F.V., Lee J.S., Murphy W.K., Lippman S.M., Calayag M., Pang A., Chasen M., Shin D.M., Glisson B., Benner S. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol. 12:1994;1238-1244.
15. Kaye S.B., Piccart M., Aapro M., Kavanagh J. Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials: EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Eur. J. Cancer (suppl. 4). 31A:1995;S14-S17.
16. Francis P., Schneider J., Hann L., Balmaceda C., Barakat R., Phillips M., Hakes T. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J. Clin. Oncol. 12:1994;2301-2308.
17. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). N. Engl. J. Med. 332:1995;1004-1014.
18. Sparreboom A., van Tellingen O., Nooijen W.J., Beijnen J.H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutica vehicle Cremophor EL. Cancer Res. 56:1996;2112-2115.
19. van Oosterom A.T., Schrijvers D. Docetaxel (Taxotere®), a review of preclinical and clinical experience. Part. II: clinical experience. Anti-Cancer Drugs. 6:1995;356-368.
20. Cortes J.E., Pazdur R. Docetaxel. J. Clin. Oncol. 13:1995;2643-2655.
21. Pazdur R., Newman R.A., Newman B.M., Fuentes A., Benvenuto J., Bready B., Moore Jr D., Jaiyesimi I., Vreeland F., Bayssas M.M. Phase I trial of Taxotere: five-day schedule. J. Natl. Cancer Inst. 84:1992;1781-1788.
22. McLeod H.L., Kearns C.M., Kuhn J.G., Bruno R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother. Pharmacol. 42:1998;155-159.
23. Extra J.-M., Rousseau F., Bruno R., Clavel M., Le Bail N., Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976, NSC 628503) given as a short intravenous infusion. Cancer Res. 53:1993;1037-1042.
24. Bruno R., Sanderink G.J. Pharmacokinetics and metabolism of Taxotere™ (docetaxel). Cancer Surv. 17:1993;305-313.
25. Monegier B., Gaillard C., Sable S., Vuilhorgne M. Structures of the major human metabolites of docetaxel (RP 56976, Taxotere®). Tetrahedron Lett. 35:1994;3715-3718.
26. Royer I., Monsarrat B., Sonnier M., Wright M., Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 56:1996;58-65.
27. Piccart M.J., Di Leo A. Future perspectives of docetaxel (Taxotere) in front-line therapy. Semin. Oncol. (suppl. 10). 24(4):1997;S27-S33.
28. Piccart M. Docetaxel: a new defence in the management of breast cancer. Anti-Cancer Drugs (suppl. 2). 7:1996;9-12.
29. D'Incalci M., Schüller J., Colombo T., Zucchetti M., Riva A. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin. Oncol. (suppl. 13). 25(6):1998;16-20.
30. O'Shaughnessy J.A., Fisherman J.S., Cowan K.H. Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin. Oncol. (suppl. 8). 21(5):1994;19-23.
31. Gianni L., Viganò L., Locatelli A., Capri G, Giani A., Tarenzi E., Bonadonna G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol. 15:1997;1906-1915.
32. Gianni L., Munzone E., Capri G, Fulfaro F., Tarenzi E., Villani F., Spreafico C., Laffranchi A., Caraceni A., Martini C., Stefanelli M., Valagussa P., Bonadonna G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastasic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol. 13:1995;2688-2699.
33. Holmes F.A., Madden T., Newman R.A., Valero V., Theriault R.L., Fraschini G., Walters R.S., Booser D.J., Buzdar A.U., Willey J., Hortobagyi G.N. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 14:1996;2713-2721.
34. Pagani O. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer. Semin. Oncol. (suppl. 12). 25(5):1998;23-26.
35. Conte P.F., Baldini E., Gennari A., Michelotti A., Salvadori B., Tibaldi C., Danesi R., Innocenti F., Gentile A., Dell'Anna R., Biadi O., Mariani M., Del Tacca M. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J. Clin. Oncol. 15:1997;2510-2517.
36. Vergniol J.C., Bruno R., Montay G., Frydman A. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J. Chromatogr. 582:1992;273-278.
37. Camaggi C.M., Comparsi R., Strocchi E., Testoni F., Angelelli B., Pannuti F. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. Cancer Chemother. Pharmacol. 21:1988;221-228.
38. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
39. Webster L., Linsenmeyer M., Millward M., Morton C., Bishop J., Woodcock D. Measurement of Cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl. Cancer Inst. 85:1993;1685-1690.
40. Woodcock D.M., Linsenmeyer M.E., Chojnowski G., Kriegler A.B., Nink V., Webster L.K., Sawyer W.H. Reversal of multidrug resistance by surfactants. Br. J. Cancer. 66:1992;62-68.